{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:10:20Z","timestamp":1759464620754,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1053\/j.ajkd.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T01:06:40Z","timestamp":1671152800000},"page":"259-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Much Ado About Something: The Clinical Pattern of Tolvaptan-Associated Liver Injury in Participants With ADPKD"],"prefix":"10.1053","volume":"81","author":[{"given":"Merve","family":"Postalcioglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cullaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1053\/j.ajkd.2022.10.004_bib1","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients\u00a0with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2022.10.004_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"10.1053\/j.ajkd.2022.10.004_bib3","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2022.10.004_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2022.08.012","article-title":"Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials","volume":"81","author":"Alpers","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2022.10.004_bib5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ekir.2019.09.002","article-title":"Role of liver transplantation in tolvaptan-associated acute liver failure","volume":"4","author":"Endo","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2022.10.004_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following drug-induced liver injury","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1053\/j.ajkd.2022.10.004_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","article-title":"Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors","volume":"155","author":"Woodhead","year":"2017","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1053\/j.ajkd.2022.10.004_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2215\/CJN.08170719","article-title":"A\u00a0post hoc analysis of statin use in tolvaptan autosomal dominant polycystic kidney disease pivotal trials","volume":"15","author":"Shoaf","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2022.10.004_bib9","first-page":"438","article-title":"Editor's highlight: candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach","volume":"156","author":"Mosedale","year":"2017","journal-title":"Toxicol Sci"},{"key":"10.1053\/j.ajkd.2022.10.004_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.648805","article-title":"Predicting drug-induced liver injury using machine learning on a diverse set of predictors","volume":"12","author":"Adeluwa","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1053\/j.ajkd.2022.10.004_bib11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10157-020-01988-4","article-title":"Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations","volume":"25","author":"Moriyama","year":"2021","journal-title":"Clin Exp Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622009994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622009994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:45:41Z","timestamp":1759463141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638622009994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0272638622009994"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.004","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Much Ado About Something: The Clinical Pattern of Tolvaptan-Associated Liver Injury in Participants With ADPKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.08.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.","name":"copyright","label":"Copyright"}]}}